NBTX Nanobiotix: Enterprise Value-to-Revenue Multiple

Nanobiotix (NBTX) - corporate logo

The EV/Revenue multiple illustrates the valuation dynamics of Nanobiotix S.A., where the current parameter stands at 142236.92, correlating with the outsourcing of production and testing to third-party contractors. The business foundation relies on its image as a leading European innovator; however, cross-border conflicts and sanctions create risks for global supply chains and the execution of international research on oncology platforms.

Nanobiotix S.A. - NBTX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

NBTX (Nanobiotix S.A.): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
- company stock capitalization data:
- cash and cash flow indicators:
Fundamental company valuation:NBTX - nanobiotix.com
Original product of Nanobiotix Group

Nanobiotix S.A. (NBTX) is developing a scalable nanoparticle platform to enhance radiotherapy for various types of cancer. The EV/Sales metric assesses the total value of the business, including debt, relative to the revenue generated. The current value of 142236.92 reflects market expectations regarding the commercialization of the technology's physical mechanism of action. The EV/Sales trajectory helps identify the risk of overpaying for future growth. This indicator determines the investment attractiveness of this high-tech biotechnological asset.